5 results about "Injectable Suspension" patented technology

The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof that inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Sustained-release oral pharmaceutical compositions comprising the pharmaceutical composition are described, as well as sustained-release injectable pharmaceutical compositions comprising the pharmaceutical composition.The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal administration comprising the pharmaceutical composition. Also described are: methods for evaluating the efficacy of the pharmaceutical composition; methods for evaluating the inhibitory or partial inhibitory activity of the pharmaceutical composition; methods for treating, alleviating, or preventing a condition or disease comprising administering a therapeutically effective amount of the pharmaceutical composition to a subject; and the use of the pharmaceutical composition for manufacturing a pharmaceutical dosage form for the treatment of a disease.

The present invention belongs to the field of pharmaceutical formulation, and particularly relates to an aripiprazole injectable suspension formulation having prolonged shelf life, and methods of using the formulation in treating schizophrenia and related diseases. In another aspect, the present invention also relates to a method of prolonging shelf life of an aripiprazole injectable suspension formulation.

To provide a method for treating a psychotic patient in need of treatment with a long-acting injectable paliperidone palmitate formulation.SOLUTION: A method for administering paliperidone palmitate to a patient in need thereof who has been administered a first dose of a first paliperidone palmitate extended release injectable suspension (first suspension), the method comprising: Administering a resumption loading dose of a second paliperidone palmitate extended release injectable suspension (second suspension) to the patient's deltoid muscle at a time point that is greater than 6 months and less than 3 weeks after administration of the first dose of the first suspension, and administering a maintenance dose of the first suspension to the patient's deltoid muscle or gluteus maximus muscle at a time point that is about 1 month (+ / -7 days) after administration of the resumption loading dose of the second suspension.SELECTED DRAWING: None

To provide a method for treating a psychotic patient in need of treatment with a long-acting injectable paliperidone palmitate formulation.SOLUTION: A method for administering paliperidone palmitate to a patient in need thereof who has been administered a first dose of paliperidone palmitate sustained release injectable suspension, comprising administering a second dose of the paliperidone palmitate sustained release injectable suspension to the deltoid or gluteal muscle of the patient up to two weeks before or three weeks after a time point that is six months after administration of the first dose, wherein there are no intervening doses of paliperidone palmitate between the first dose and the second dose.SELECTED DRAWING: None

The present invention relates to an injectable suspension or emulsion of magnetite nanoparticles coated with an organic layer, which can be used for the treatment of solid tumors.